New drug combo aims to fight lung cancer without chemo

NCT ID NCT06322108

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether two immunotherapy drugs, balstilimab and botensilimab, are safe and effective as a first treatment for people with metastatic non-small cell lung cancer. The trial includes 45 participants who have not had prior treatment for advanced disease. Researchers will track how long patients live without their cancer getting worse, and how many respond to the drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
balstilimab and botensilimab (immunotherapy drugs)
What this could lead to
If successful, this combination could offer a new first-line immunotherapy option for people with metastatic non-small cell lung cancer, potentially improving survival without chemotherapy.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 45 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hematology Center named after prof. R. Yeolyan

    Yerevan, 0014, Armenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.